观点：抗血管内皮生长因子-A和血管生成素-2的双阻断抗体治疗眼部血管疾病
Viewpoints: Dual-blocking antibody against VEGF-A and angiopoietin-2 for treating vascular diseases of the eye.
作者信息
Koh Gou Young, Augustin Hellmut G, Campochiaro Peter A
机构信息
Center for Vascular Research, Institute for Basic Science, Daejeon, Republic of Korea; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Division of Vascular Oncology and Metastasis, German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Germany; European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Germany.
出版信息
Trends Mol Med. 2022 May;28(5):347-349. doi: 10.1016/j.molmed.2022.03.004. Epub 2022 Apr 5.
Faricimab, a bispecific antibody that targets the endothelial cell growth factors vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Angpt2), was recently approved for treating neovascular age-related macular degeneration and diabetic macular edema. Here, Koh and Augustin review how mechanistic studies have translated into therapies, while Campochiaro evaluates their impact and value for clinical practice.
法西单抗是一种靶向血管内皮生长因子-A（VEGF-A）和血管生成素-2（Angpt2）这两种内皮细胞生长因子的双特异性抗体，最近被批准用于治疗新生血管性年龄相关性黄斑变性和糖尿病性黄斑水肿。在此， Koh和Augustin回顾了机制研究如何转化为治疗方法，而Campochiaro则评估了它们对临床实践的影响和价值。
Zotero 插件